| Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia JC Byrd, JR Brown, S O'Brien, JC Barrientos, NE Kay, NM Reddy, ... New England Journal of Medicine 371 (3), 213-223, 2014 | 2020 | 2014 |
| Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia JA Burger, A Tedeschi, PM Barr, T Robak, C Owen, P Ghia, O Bairey, ... New England Journal of Medicine 373 (25), 2425-2437, 2015 | 1845 | 2015 |
| Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma WH Wilson, RM Young, R Schmitz, Y Yang, S Pittaluga, G Wright, CJ Lih, ... Nature medicine 21 (8), 922-926, 2015 | 1280 | 2015 |
| Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL JA Woyach, AS Ruppert, NA Heerema, W Zhao, AM Booth, W Ding, ... New England Journal of Medicine 379 (26), 2517-2528, 2018 | 1040 | 2018 |
| Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia TD Shanafelt, XV Wang, NE Kay, CA Hanson, S O’Brien, J Barrientos, ... New England Journal of Medicine 381 (5), 432-443, 2019 | 819 | 2019 |
| Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study JA Burger, PM Barr, T Robak, C Owen, P Ghia, A Tedeschi, O Bairey, ... Leukemia 34 (3), 787-798, 2020 | 541 | 2020 |
| Final analysis from RESONATE: up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma T Munir, JR Brown, S O'Brien, JC Barrientos, PM Barr, NM Reddy, ... American journal of hematology 94 (12), 1353-1363, 2019 | 505 | 2019 |
| Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis AR Mato, C Nabhan, MC Thompson, N Lamanna, DM Brander, B Hill, ... Haematologica 103 (5), 874, 2018 | 467 | 2018 |
| Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial JA Jones, AR Mato, WG Wierda, MS Davids, M Choi, BD Cheson, ... The lancet oncology 19 (1), 65-75, 2018 | 447 | 2018 |
| Outcomes of COVID-19 in patients with CLL: a multicenter international experience AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ... Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020 | 323 | 2020 |
| US intergroup trial of response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose–positron emission tomography imaging: Southwest … OW Press, H Li, H Schöder, DJ Straus, CH Moskowitz, M LeBlanc, ... Journal of Clinical Oncology 34 (17), 2020-2027, 2016 | 309 | 2016 |
| Postibrutinib outcomes in patients with mantle cell lymphoma P Martin, K Maddocks, JP Leonard, J Ruan, A Goy, N Wagner-Johnston, ... Blood, The Journal of the American Society of Hematology 127 (12), 1559-1563, 2016 | 304 | 2016 |
| Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL JR Brown, P Hillmen, S O’brien, JC Barrientos, NM Reddy, SE Coutre, ... Leukemia 32 (1), 83-91, 2018 | 277 | 2018 |
| Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients AR Mato, BT Hill, N Lamanna, PM Barr, CS Ujjani, DM Brander, C Howlett, ... Annals of Oncology 28 (5), 1050-1056, 2017 | 271 | 2017 |
| Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab JC Byrd, P Hillmen, S O’Brien, JC Barrientos, NM Reddy, S Coutre, ... Blood, The Journal of the American Society of Hematology 133 (19), 2031-2042, 2019 | 263 | 2019 |
| The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma … WH Wilson, JF Gerecitano, A Goy, S de Vos, VP Kenkre, PM Barr, ... Blood 120 (21), 686, 2012 | 262 | 2012 |
| Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy V Jurinovic, R Kridel, AM Staiger, M Szczepanowski, H Horn, MH Dreyling, ... Blood, The Journal of the American Society of Hematology 128 (8), 1112-1120, 2016 | 245 | 2016 |
| Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience AR Mato, C Nabhan, PM Barr, CS Ujjani, BT Hill, N Lamanna, ... Blood, The Journal of the American Society of Hematology 128 (18), 2199-2205, 2016 | 227 | 2016 |
| Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia PM Barr, C Owen, T Robak, A Tedeschi, O Bairey, JA Burger, P Hillmen, ... Blood advances 6 (11), 3440-3450, 2022 | 215 | 2022 |
| Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase II CheckMate 436 study PL Zinzani, A Santoro, G Gritti, P Brice, PM Barr, J Kuruvilla, ... Journal of Clinical Oncology 37 (33), 3081-3089, 2019 | 193 | 2019 |